A nationwide cohort from Taiwan involving 810 SGLT2 inhibitor users revealed a 29% lower risk of developing dementia (HR: 0.71, 95% CI: 0.51–0.98), particularly vascular dementia (HR: 0.44, 95% CI: 0.24–0.82), compared to non-users. This evidence concerns the gene SLC5A2 and vascular dementia.